{"id":"NCT02968368","sponsor":"Shield Therapeutics","briefTitle":"Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease","officialTitle":"A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-01","primaryCompletion":"2018-01-18","completion":"2018-10-10","firstPosted":"2016-11-18","resultsPosted":"2020-05-01","lastUpdate":"2020-11-02"},"enrollment":167,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Renal Insufficiency, Chronic","Iron-Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferric maltol","otherNames":["Feraccru"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Oral ferric maltol","type":"EXPERIMENTAL"},{"label":"Oral placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD","primaryOutcome":{"measure":"Change in Hb Concentration From Baseline to Week 16","timeFrame":"16 weeks","effectByArm":[{"arm":"Oral Ferric Maltol","deltaMin":0.5,"sd":0.122},{"arm":"Oral Placebo","deltaMin":-0.02,"sd":0.165}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0149"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["34029682"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":111},"commonTop":["Gastrointestinal disorders","Infections and infestations","Metabolism and nutrition disorders","Constipation","Nausea"]}}